Loading...

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

BACKGROUND: Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated w...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Langley, Ruth E, Cafferty, Fay H, Alhasso, Abdulla A, Rosen, Stuart D, Sundaram, Subramanian Kanaga, Freeman, Suzanne C, Pollock, Philip, Jinks, Rachel C, Godsland, Ian F, Kockelbergh, Roger, Clarke, Noel W, Kynaston, Howard G, Parmar, Mahesh KB, Abel, Paul D
Format: Artigo
Sprog:Inglês
Udgivet: Lancet Pub. Group 2013
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3620898/
https://ncbi.nlm.nih.gov/pubmed/23465742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70025-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!